EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
Special Offer: Just $199
×
S&P 500   3,957.63 (-0.16%)
DOW   33,852.53 (+0.01%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
S&P 500   3,957.63 (-0.16%)
DOW   33,852.53 (+0.01%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
S&P 500   3,957.63 (-0.16%)
DOW   33,852.53 (+0.01%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
S&P 500   3,957.63 (-0.16%)
DOW   33,852.53 (+0.01%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
Top-Rated Stocks  
NASDAQ:RCKT

Rocket Pharmaceuticals - RCKT Stock Forecast, Price & News

$18.08
+0.55 (+3.14%)
(As of 11/29/2022 04:15 PM ET)
Add
Compare
Today's Range
$17.66
▼
$18.55
50-Day Range
$12.37
▼
$20.70
52-Week Range
$7.57
▼
$25.62
Volume
456,819 shs
Average Volume
761,720 shs
Market Capitalization
$1.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.40

Rocket Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
211.4% Upside
$56.40 Price Target
Short Interest
Healthy
10.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
0.93mentions of Rocket Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$20 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.98) to ($2.95) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.02 out of 5 stars

Medical Sector

16th out of 1,038 stocks

Pharmaceutical Preparations Industry

6th out of 510 stocks

See Top Rated MarketRank™ Stocks Here
RCKT stock logo

About Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.

Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCKT Stock News Headlines

November 29, 2022 | seekingalpha.com
Rocket Pharmaceuticals: 2 Regulatory Filings In 2023 Could Propel It Higher
November 21, 2022 | finance.yahoo.com
Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 18, 2022 | seekingalpha.com
Rocket Pharmaceuticals: Intriguing Potential
November 4, 2022 | finance.yahoo.com
Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
November 3, 2022 | finance.yahoo.com
Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses
October 30, 2022 | msn.com
Hogs’ ‘Rocket’ Sanders Still Has Goals in Front of Him
October 27, 2022 | finance.yahoo.com
Wall Street Analysts See an 184% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?
October 14, 2022 | finance.yahoo.com
Alkermes, Allakos, and Other Stocks See Action From Activist Investors
October 12, 2022 | finance.yahoo.com
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
October 11, 2022 | finance.yahoo.com
Does Rocket Pharmaceuticals (RCKT) Have the Potential to Rally 212% as Wall Street Analysts Expect?
October 10, 2022 | finance.yahoo.com
Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa
October 4, 2022 | nasdaq.com
Rocket Pharmaceuticals Adds 10%; Prices 6.8 Mln Share Offering
October 4, 2022 | nasdaq.com
Rocket Pharma Prices Public Offering Of 6.80 Mln Shares At $14.75/shr
September 30, 2022 | seekingalpha.com
Rocket's gene therapy for heart disease shows promise in children/adults in phase 1 trial
September 30, 2022 | finance.yahoo.com
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
September 27, 2022 | markets.businessinsider.com
Needham Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)
September 27, 2022 | finance.yahoo.com
Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference
September 20, 2022 | nasdaq.com
Rocket Pharma To Buy Renovacor For $2.60/ Share In Stock
September 20, 2022 | marketwatch.com
Rocket Pharmaceuticals to Acquire Renovacor in All-Stk Transaction for Implied Value of About $2.60 Per Shr >RCKT
September 20, 2022 | technews.tmcnet.com
RCKT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Rocket Pharmaceuticals, Inc. Is Fair to Shareholders
September 20, 2022 | seekingalpha.com
Rocket to acquire heart gene-therapy developer Renovacor in all-stock deal
September 20, 2022 | finance.yahoo.com
Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy
September 20, 2022 | finance.yahoo.com
Rocket Pharmaceuticals Buys Renovacor, Strengthening Position In Gene Therapies For Heart Diseases
September 16, 2022 | finance.yahoo.com
Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
September 16, 2022 | msn.com
Rocket Lab celebrates 30th launch and 150th satellite sent to orbit
See More Headlines
Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCKT Company Calendar

Last Earnings
11/03/2021
Today
11/29/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RCKT
CUSIP
N/A
CIK
1281895
Web
www.rocketpharma.com
Phone
(646) 440-9100
Fax
646-224-9585
Employees
151
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$56.40
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+211.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-169,070,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-49.01%
Return on Assets
-44.15%

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
10.31
Quick Ratio
10.31

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.05 per share
Price / Book
2.56

Miscellaneous

Outstanding Shares
75,684,000
Free Float
50,201,000
Market Cap
$1.37 billion
Optionable
Optionable
Beta
1.48

Key Executives

  • Dr. Gaurav D. Shah M.D. (Age 47)
    CEO & Director
    Comp: $920.2k
  • Ms. Kinnari Patel M.B.A. (Age 43)
    MBA, Pharm.D., PharmD, Pres & COO
    Comp: $717.82k
  • Mr. Martin Louis Wilson J.D. (Age 46)
    Gen. Counsel, Chief Compliance Officer & Sr. VP
    Comp: $149.95k
  • Mr. Jonathan Schwartz (Age 58)
    Chief Medical Officer & Sr. VP of Clinical Devel.
    Comp: $557.79k
  • Mr. John C. Militello CPA (Age 49)
    CPA, Interim Principal Financial Officer, VP, Sr. Controller, Treasurer & Principal Accounting Officer
  • Mr. Mayo Pujols
    Chief Technical Officer, Exec. VP & Director
  • Mayur Kasetty M.B.A.
    M.D., Bus. Devel. & Operations and Investor Relations Lead
  • Ms. Jessie Yeung M.B.A.
    VP of Investor Relations & Corp. Fin.
  • Kevin Giordano
    Director of Corp. Communications
  • Ms. Isabel Carmona J.D.
    Sr. VP & Chief HR Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













RCKT Stock - Frequently Asked Questions

Should I buy or sell Rocket Pharmaceuticals stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RCKT shares.
View RCKT analyst ratings or view top-rated stocks.

What is Rocket Pharmaceuticals' stock price forecast for 2023?

10 Wall Street analysts have issued 12 month target prices for Rocket Pharmaceuticals' stock. Their RCKT share price forecasts range from $34.00 to $75.00. On average, they anticipate the company's share price to reach $56.40 in the next year. This suggests a possible upside of 213.0% from the stock's current price.
View analysts price targets for RCKT or view top-rated stocks among Wall Street analysts.

How have RCKT shares performed in 2022?

Rocket Pharmaceuticals' stock was trading at $21.83 at the beginning of the year. Since then, RCKT shares have decreased by 17.5% and is now trading at $18.02.
View the best growth stocks for 2022 here.

When is Rocket Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our RCKT earnings forecast.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) released its earnings results on Wednesday, November, 3rd. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.60) by $0.19. During the same period in the prior year, the company posted ($0.53) earnings per share.

What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).

What is Rocket Pharmaceuticals' stock symbol?

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.94%), Vanguard Group Inc. (4.52%), State Street Corp (4.48%), Price T Rowe Associates Inc. MD (2.17%), Assenagon Asset Management S.A. (2.10%) and Dimensional Fund Advisors LP (1.17%). Insiders that own company stock include Gaurav Shah, Gotham Makker, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rocket Pharmaceuticals' stock price today?

One share of RCKT stock can currently be purchased for approximately $18.02.

How much money does Rocket Pharmaceuticals make?

Rocket Pharmaceuticals (NASDAQ:RCKT) has a market capitalization of $1.36 billion. The biotechnology company earns $-169,070,000.00 in net income (profit) each year or ($3.06) on an earnings per share basis.

How many employees does Rocket Pharmaceuticals have?

The company employs 151 workers across the globe.

How can I contact Rocket Pharmaceuticals?

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The official website for the company is www.rocketpharma.com. The biotechnology company can be reached via phone at (646) 440-9100, via email at investors@rocketpharma.com, or via fax at 646-224-9585.

This page (NASDAQ:RCKT) was last updated on 11/29/2022 by MarketBeat.com Staff